Xintela broadens and extends patent protection for chondrocyte products and chondrocyte markers

Lund, Sweden, 8 January 2019 – Xintela announces today that the company's international (PCT) patent application for quality-assured chondrocytes (cartilage cells), developed using the company's integrin markers, was published on January 3, 2019 under publication number WO 2019/002547.

The patent application relates to a further development of Xintela's marker technology and quality test XACT and protects chondrocyte preparations of high-quality and purity as well as methods to isolate chondrocytes using a combination of the cell markers integrin a10b1 and integrin a11b1. Chondrocytes, quality assured with Xintela's quality assay XACT have both regulatory and functional advantages in cell therapy of cartilage damage. The European Patent Office (EPO), which has examined the international patent application, has concluded that it is both novel and inventive.

“This patent application demonstrates our proactive approach to create strong and long-term protection of our portfolio technologies and importantly, it also strengthens our position in collaboration discussions with companies that develop chondrocyte products. The positive examination report from the EPO is very promising, not least considering that the national patent authorities in many other territories tends to follow the opinion of the EPO in their assessments”, says Xintela's CEO Evy Lundgren-Åkerlund.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy [at]
Medicon Village
223 81 Lund 

Xintela AB